ATE435297T1 - Retrovirales verabreichungssystem - Google Patents

Retrovirales verabreichungssystem

Info

Publication number
ATE435297T1
ATE435297T1 AT99922378T AT99922378T ATE435297T1 AT E435297 T1 ATE435297 T1 AT E435297T1 AT 99922378 T AT99922378 T AT 99922378T AT 99922378 T AT99922378 T AT 99922378T AT E435297 T1 ATE435297 T1 AT E435297T1
Authority
AT
Austria
Prior art keywords
retroviral
delivery system
target site
nucleotide sequence
retroviral delivery
Prior art date
Application number
AT99922378T
Other languages
English (en)
Inventor
Kyriacos Mitraphanous
Deva Patil
Alan Kingsman
Susan Mary Kingsman
Fiona Margaret Ellard
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9811153A external-priority patent/GB2337520B/en
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE435297T1 publication Critical patent/ATE435297T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
AT99922378T 1998-05-22 1999-05-21 Retrovirales verabreichungssystem ATE435297T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9811153A GB2337520B (en) 1998-05-22 1998-05-22 Delivery system
US9314998P 1998-07-17 1998-07-17
PCT/GB1999/001607 WO1999061639A2 (en) 1998-05-22 1999-05-21 Retroviral delivery system

Publications (1)

Publication Number Publication Date
ATE435297T1 true ATE435297T1 (de) 2009-07-15

Family

ID=26313732

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922378T ATE435297T1 (de) 1998-05-22 1999-05-21 Retrovirales verabreichungssystem

Country Status (10)

Country Link
EP (1) EP1080216B1 (de)
JP (1) JP4612950B2 (de)
KR (1) KR20010074493A (de)
CN (1) CN1325653C (de)
AT (1) ATE435297T1 (de)
AU (1) AU763007B2 (de)
CA (1) CA2328491A1 (de)
DE (1) DE69941049D1 (de)
GB (1) GB2351290A (de)
WO (1) WO1999061639A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036170A2 (en) * 2000-11-03 2002-05-10 Oxford Biomedica (Uk) Limited Vector system for transducing the positive neurons
EP1852511B1 (de) * 1999-12-14 2010-02-17 Novartis AG Auf bovinem Immundefizienvirus (BIV) basierende Vektoren
GB0024550D0 (de) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
WO2003016539A1 (en) * 2001-03-13 2003-02-27 Thomas Jefferson University Retroviral vectors for gene transfer into neuronal cells
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
FR2825372B1 (fr) * 2001-06-01 2004-06-18 Centre Nat Rech Scient Pseudotypage des vecteurs vih-1 par des enveloppes de rhabdovirus
WO2003025188A1 (en) * 2001-09-14 2003-03-27 Oxford Biomedica (Uk) Limited Use of a lentiviral vector in the treatment of pain
JP4598398B2 (ja) 2002-02-01 2010-12-15 オックスフォード バイオメディカ （ユーケー） リミテッド ウイルスベクター
JP2006502240A (ja) * 2002-10-04 2006-01-19 オックスフォード バイオメディカ （ユーケー） リミテッド ベクター系
WO2006028302A1 (en) * 2004-09-07 2006-03-16 Macrogen Co., Ltd Caev-based vector systems
WO2006120473A2 (en) 2005-05-13 2006-11-16 Oxford Biomedica (Uk) Limited Mhc class i and ii peptide antigens derived from tumour antigen 5t4
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
CN103993040B (zh) 2008-06-18 2018-02-13 牛津生物医学（英国）有限公司 病毒纯化
SG177744A1 (en) * 2009-07-24 2012-02-28 Immune Design Corp Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
DK2575894T3 (en) 2010-05-28 2015-05-26 Oxford Biomedica Ltd FEED lentiviral vectors FOR BRAIN
CN103328038A (zh) 2010-12-01 2013-09-25 史拜诺莫度雷森公司 向神经解剖结构直接递送药剂
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
US20160122727A1 (en) 2013-06-13 2016-05-05 Shire Human Genetic Therapies, Inc. Messenger rna based viral production
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
GB201715052D0 (en) * 2017-09-19 2017-11-01 Oxford Genetics Ltd Vectors
EP3937985A1 (de) 2019-03-10 2022-01-19 Sio Gene Therapies Inc. Gentherapiezusammensetzungen und verfahren zur behandlung von morbus parkinson
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0261940A3 (de) * 1986-09-23 1989-07-05 Applied Biotechnology, Inc. Pseudorabies-Impfstoffe und DNS-Vektoren zur Rekombination mit Poxviren
CA2089497A1 (en) * 1990-08-15 1992-02-16 Lendon Payne Self-assembling replication defective hybrid virus particles
JP3547129B2 (ja) * 1991-02-19 2004-07-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 変更宿主域を有するウィルス粒子
WO1993001833A1 (en) * 1991-07-17 1993-02-04 Commonwealth Scientific And Industrial Research Organisation Improved vaccine
WO1993014188A1 (en) * 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
ZA937164B (en) * 1992-09-28 1994-05-23 Commw Scient Ind Res Org Delivery system
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
AU3635695A (en) * 1994-09-19 1996-04-09 Board Of Trustees Of The Leland Stanford Junior University Methods for genetically modifying hematopoietic stem cells
US5739018A (en) * 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors

Also Published As

Publication number Publication date
WO1999061639A3 (en) 2000-01-27
WO1999061639A2 (en) 1999-12-02
JP2002518997A (ja) 2002-07-02
EP1080216B1 (de) 2009-07-01
KR20010074493A (ko) 2001-08-04
AU763007B2 (en) 2003-07-10
AU3947399A (en) 1999-12-13
GB2351290A (en) 2000-12-27
DE69941049D1 (de) 2009-08-13
CA2328491A1 (en) 1999-12-02
CN1302334A (zh) 2001-07-04
EP1080216A2 (de) 2001-03-07
CN1325653C (zh) 2007-07-11
JP4612950B2 (ja) 2011-01-12
GB0024915D0 (en) 2000-11-22

Similar Documents

Publication Publication Date Title
DE69941049D1 (de) Retrovirales verabreichungssystem
NO20014364L (no) Ny cytokin-zalphall-ligand
DK0776331T3 (da) Struktur af højere orden og binding af peptidnukleinsyrer
NO20043419L (no) Nytt cytokin, zcytor17-ligand
NO2013009I1 (no) Alipogen tiparvovec
WO2001064835A8 (en) Novel nucleic acids and polypeptides
HUP0100094A1 (hu) Új felületi antigén
FI965031A0 (fi) Sieni, jossa AreA-geeni on muunnettu, ja Aspergillus oryzaesta peräisin oleva areA-geeni
WO1996012809A3 (fr) Sequences nucleotidiques d'antigenes retroviraux vih-1 groupe (ou sous-groupe) o
DE69230535T2 (de) Polyphenol oxidase gene
ATE429929T1 (de) Verbesserte impfstoffe
NO974035D0 (no) En ny vestfaktor og en genetisk sekvens som koder for denne
GB0202569D0 (en) Delivery means
NO970030L (no) Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2
DE69629808D1 (de) Promtors für gen expression
WO2002022663A3 (en) Stress resistant retroviruses
DE69823188D1 (de) Klonierung der udp-galaktose-epimerase
AU2002341238A1 (en) Diabetic model
EA199801007A1 (ru) Способ биосинтеза, позволяющий получать кобаламины
WO2002083727A3 (de) Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse
EA200100440A1 (ru) Ген prv-1 и его применение
EA200200286A1 (ru) Ген prv-1 и его применение
DK1123396T3 (da) Minimale promotorer og anvendelser deraf
ES2260624T3 (es) Deteccion de mutaciones.
EA200000705A1 (ru) Промежуточные соединения и способ синтеза 17-замещенных 16.бета.-арилокси 4-азастероидов

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties